{"id":37885,"date":"2025-07-24T17:05:59","date_gmt":"2025-07-24T09:05:59","guid":{"rendered":"https:\/\/flcube.com\/?p=37885"},"modified":"2025-07-24T17:05:59","modified_gmt":"2025-07-24T09:05:59","slug":"boehringer-ingelheim-reports-6-3-sales-growth-in-first-half-of-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37885","title":{"rendered":"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025"},"content":{"rendered":"\n<p>Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of \u20ac14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of \u20ac11.3 billion, and its Animal Health business, contributing \u20ac2.6 billion.<\/p>\n\n\n\n<p><strong>Human Pharma Business Growth<\/strong><br>The Human Pharma business saw a 5.7% increase in net sales to \u20ac11.3 billion. This growth was driven by robust global demand for key products such as JARDIANCE and OFEV. JARDIANCE, indicated for chronic kidney disease, type 2 diabetes, and heart failure, generated sales of \u20ac4.3 billion. OFEV, used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, contributed \u20ac2.0 billion to the sales.<\/p>\n\n\n\n<p><strong>Late-Stage Pipeline Advances<\/strong><br>Boehringer Ingelheim is also making strides in its late-stage pipeline. Zongertinib, a targeted therapy for HER2-mutant advanced non-small cell lung cancer (NSCLC), has shown durable responses and clinically meaningful results in previously treated patients, with over 70% experiencing a tumor response. It is currently under regulatory review in the U.S., Japan, and China and is being evaluated as a first-line treatment in a global Phase III trial.<\/p>\n\n\n\n<p>Nerandomilast, a potential therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), demonstrated significant slowing of lung-function decline in two FIBRONEER Phase III trials. It was well tolerated, with discontinuation rates comparable to placebo. Regulatory submissions for nerandomilast have been made in the U.S., EU, China, and Japan.<\/p>\n\n\n\n<p><strong>Global Supply Network Expansion<\/strong><br>To support future product launches and sustained growth, Boehringer Ingelheim is enhancing its global supply network. A key milestone is the \u20ac300 million investment in its Yamagata site in Japan. This includes the opening of a new production unit, infrastructure upgrades, and the groundbreaking for an additional facility in June. This expansion positions Japan as a critical production hub for the Asia and Oceania regions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/Boehringer-Ingelheim-half-year-results-2025-Boehringer-Ingelheim.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Boehringer Ingelheim half-year results 2025 | Boehringer Ingelheim.\"><\/object><a id=\"wp-block-file--media-48e3b62c-de28-440f-9737-95afd22aa80e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/Boehringer-Ingelheim-half-year-results-2025-Boehringer-Ingelheim.pdf\">Boehringer Ingelheim half-year results 2025 | Boehringer Ingelheim<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/Boehringer-Ingelheim-half-year-results-2025-Boehringer-Ingelheim.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-48e3b62c-de28-440f-9737-95afd22aa80e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37888,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[390,27],"class_list":["post-37885","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-boehringer-ingelheim","tag-finanical-reports"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of \u20ac14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of \u20ac11.3 billion, and its Animal Health business, contributing \u20ac2.6 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37885\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of \u20ac14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of \u20ac11.3 billion, and its Animal Health business, contributing \u20ac2.6 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37885\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-24T09:05:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2407.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025\",\"datePublished\":\"2025-07-24T09:05:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2407.webp\",\"keywords\":[\"Boehringer Ingelheim\",\"Finanical Reports\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37885#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37885\",\"name\":\"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2407.webp\",\"datePublished\":\"2025-07-24T09:05:59+00:00\",\"description\":\"Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of \u20ac14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of \u20ac11.3 billion, and its Animal Health business, contributing \u20ac2.6 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37885\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2407.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2407.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37885#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of \u20ac14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of \u20ac11.3 billion, and its Animal Health business, contributing \u20ac2.6 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37885","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025","og_description":"Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of \u20ac14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of \u20ac11.3 billion, and its Animal Health business, contributing \u20ac2.6 billion.","og_url":"https:\/\/flcube.com\/?p=37885","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-24T09:05:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2407.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37885#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37885"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025","datePublished":"2025-07-24T09:05:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37885"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37885#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2407.webp","keywords":["Boehringer Ingelheim","Finanical Reports"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37885#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37885","url":"https:\/\/flcube.com\/?p=37885","name":"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37885#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37885#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2407.webp","datePublished":"2025-07-24T09:05:59+00:00","description":"Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group net sales of \u20ac14 billion (approximately $16.7 billion USD), marking a 6.3% year-on-year increase. This growth was primarily attributed to its Human Pharma business, which achieved net sales of \u20ac11.3 billion, and its Animal Health business, contributing \u20ac2.6 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37885#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37885"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37885#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2407.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2407.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37885#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2407.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37885"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37885\/revisions"}],"predecessor-version":[{"id":37889,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37885\/revisions\/37889"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37888"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}